 Liposomes
"Liposomes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Artificial, single or multilaminar vesicles (made from lecithins or other lipids) that are used for the delivery of a variety of biological molecules or molecular complexes to cells, for example, drug delivery and gene transfer. They are also used to study membranes and membrane proteins.
| Descriptor ID |
D008081
|
| MeSH Number(s) |
D25.479.517 D26.255.260.517 J01.637.051.479.517 J01.637.087.500.517
|
| Concept/Terms |
Transferosomes- Transferosomes
- Transferosome
- Ultradeformable Liposomes
- Liposome, Ultradeformable
- Liposomes, Ultradeformable
- Ultradeformable Liposome
- Liposomes, Ultra-deformable
- Liposome, Ultra-deformable
- Liposomes, Ultra deformable
- Ultra-deformable Liposome
- Ultra-deformable Liposomes
|
Below are MeSH descriptors whose meaning is more general than "Liposomes".
Below are MeSH descriptors whose meaning is more specific than "Liposomes".
This graph shows the total number of publications written about "Liposomes" by people in this website by year, and whether "Liposomes" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 2 | 2 | | 1997 | 1 | 4 | 5 | | 1998 | 1 | 0 | 1 | | 1999 | 0 | 3 | 3 | | 2000 | 1 | 1 | 2 | | 2001 | 1 | 4 | 5 | | 2002 | 0 | 1 | 1 | | 2003 | 1 | 2 | 3 | | 2004 | 1 | 3 | 4 | | 2005 | 1 | 4 | 5 | | 2006 | 4 | 3 | 7 | | 2007 | 0 | 2 | 2 | | 2008 | 2 | 5 | 7 | | 2009 | 3 | 3 | 6 | | 2010 | 1 | 3 | 4 | | 2011 | 1 | 5 | 6 | | 2012 | 2 | 4 | 6 | | 2013 | 2 | 5 | 7 | | 2014 | 4 | 2 | 6 | | 2015 | 2 | 2 | 4 | | 2016 | 0 | 2 | 2 | | 2017 | 4 | 3 | 7 | | 2018 | 0 | 2 | 2 | | 2019 | 2 | 5 | 7 | | 2020 | 1 | 1 | 2 | | 2021 | 1 | 2 | 3 | | 2022 | 2 | 3 | 5 | | 2023 | 2 | 3 | 5 | | 2024 | 1 | 5 | 6 | | 2025 | 1 | 2 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Liposomes" by people in Profiles.
-
Haley RM, Padilla MS, El-Mayta RD, Joseph RA, Weber JA, Figueroa-Espada CG, Mukalel AJ, Ricciardi AS, Palanki R, Geisler HC, Jester MT, Davidson BL, Mitchell MJ. Lipid Nanoparticles for In Vivo Lung Delivery of CRISPR-Cas9 Ribonucleoproteins Allow Gene Editing of Clinical Targets. ACS Nano. 2025 04 15; 19(14):13790-13804.
-
Patel M, Panja S, Zaman LA, Yeapuri P, Bhattarai S, Gorantla S, Chang L, Heredia A, Walczak P, Hanson B, Cohen SM, Kevadiya BD, Gendelman HE. CCR5-ligand decorated rilpivirine lipid-based nanoparticles for sustained antiretroviral responses. Nat Commun. 2025 Jan 08; 16(1):513.
-
Ander SE, Davenport BJ, Evans AB, Morrison TE. Systemic Clodronate Liposome Treatment for Depletion of Blood-Contacting Phagocytes and Investigation of Their Role in the Control of Bunyavirus Viremia. Methods Mol Biol. 2025; 2893:285-298.
-
Hwang YH, Shepherd SJ, Kim D, Mukalel AJ, Mitchell MJ, Issadore DA, Lee D. Robust, Scalable Microfluidic Manufacturing of RNA-Lipid Nanoparticles Using Immobilized Antifouling Lubricant Coating. ACS Nano. 2025 01 14; 19(1):1090-1102.
-
Jogdeo CM, Siddhanta K, Das A, Ding L, Panja S, Kumari N, Oupick? D. Beyond Lipids: Exploring Advances in Polymeric Gene Delivery in the Lipid Nanoparticles Era. Adv Mater. 2024 Aug; 36(31):e2404608.
-
Hamilton AG, Swingle KL, Thatte AS, Mukalel AJ, Safford HC, Billingsley MM, El-Mayta RD, Han X, Nachod BE, Joseph RA, Metzloff AE, Mitchell MJ. High-Throughput In Vivo Screening Identifies Differential Influences on mRNA Lipid Nanoparticle Immune Cell Delivery by Administration Route. ACS Nano. 2024 06 25; 18(25):16151-16165.
-
Anchordoquy T, Artzi N, Balyasnikova IV, Barenholz Y, La-Beck NM, Brenner JS, Chan WCW, Decuzzi P, Exner AA, Gabizon A, Godin B, Lai SK, Lammers T, Mitchell MJ, Moghimi SM, Muzykantov VR, Peer D, Nguyen J, Popovtzer R, Ricco M, Serkova NJ, Singh R, Schroeder A, Schwendeman AA, Straehla JP, Teesalu T, Tilden S, Simberg D. Mechanisms and Barriers in Nanomedicine: Progress in the Field and Future Directions. ACS Nano. 2024 06 04; 18(22):13983-13999.
-
Li Y, Ettah U, Jacques S, Gaikwad H, Monte A, Dylla L, Guntupalli S, Moghimi SM, Simberg D. Optimized Enzyme-Linked Immunosorbent Assay for Anti-PEG Antibody Detection in Healthy Donors and Patients Treated with PEGylated Liposomal Doxorubicin. Mol Pharm. 2024 Jun 03; 21(6):3053-3060.
-
Spigel DR, Dowlati A, Chen Y, Navarro A, Yang JC, Stojanovic G, Jove M, Rich P, Andric ZG, Wu YL, Rudin CM, Chen H, Zhang L, Yeung S, Benzaghou F, Paz-Ares L, Bunn PA. RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer. J Clin Oncol. 2024 Jul 01; 42(19):2317-2326.
-
Palanki R, Bose SK, Dave A, White BM, Berkowitz C, Luks V, Yaqoob F, Han E, Swingle KL, Menon P, Hodgson E, Biswas A, Billingsley MM, Li L, Yiping F, Carpenter M, Trokhan A, Yeo J, Johana N, Wan TY, Alameh MG, Bennett FC, Storm PB, Jain R, Chan J, Weissman D, Mitchell MJ, Peranteau WH. Ionizable Lipid Nanoparticles for Therapeutic Base Editing of Congenital Brain Disease. ACS Nano. 2023 07 25; 17(14):13594-13610.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|